Xintela AB
Xintela AB operates with a negative equity position of -5.27 million SEK and a cash and equivalents balance of 23.21 million SEK, indicating a liquidity cushion despite a negative net income of -48.56 million SEK. The company's market capitalization is 196.37 million SEK, with a market price of 0.228 SEK per share. The enterprise value to revenue ratio is 75.88, suggesting a high valuation relative to its revenue of 2.28 million SEK. Profitability metrics reveal a challenging financial position. The company's return on equity is 9.21%, which is unusually high given the negative net income, likely due to the negative equity base. The return on assets is -1.67%, indicating that the company is not generating returns from its asset base. The operating income is -46.68 million SEK, and the operating cash flow is -41.62 million SEK, highlighting significant operational losses. Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, the lack of segmental breakdown suggests a potential risk of over-reliance on a single product or market. The absence of capital expenditures indicates that the company is not investing in new projects or infrastructure, which could limit future growth. The company's growth trajectory is constrained by its current financial performance. The revenue of 2.28 million SEK is not accompanied by positive growth indicators, and the outlook for the current and next fiscal years does not show improvement. The company's negative operating cash flow and free cash flow of -41.62 million SEK and -47.96 million SEK, respectively, suggest ongoing cash burn without clear signs of a turnaround. Risk factors include a low liquidity position, as indicated by the current ratio of 0.84, and a negative equity position. The company has no immediate filing-based liquidity or dilution flags, but the negative net income and operating cash flow pose ongoing risks. The dilution potential is low, and no adjustments have been applied to the valuation metrics. Recent events and filings do not indicate any significant changes in the company's strategic direction or financial status. The absence of recent capital raising activities or major business developments suggests a period of operational stagnation.
Business. Xintela AB is a biotechnology company focused on healthcare diagnostics, primarily generating revenue through the development and commercialization of diagnostic solutions.
Classification. Xintela is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.
- Xintela AB is a biotechnology company with a negative equity position and significant operational losses.
- The company's high enterprise value to revenue ratio suggests a speculative valuation.
- The lack of capital expenditures and segmental revenue breakdown indicates limited diversification and growth potential.
- The company's liquidity position is weak, with a current ratio below 1 and negative net income.
- No immediate dilution or liquidity flags are present, but ongoing cash burn remains a concern.
- --
- ## RATIONALES
- ```json
- No immediate filing-based liquidity or dilution flags were detected.